Werewolf Therapeutics, a preclinical biotech developing immune therapies for cancer, filed on Thursday with the SEC to raise up to $100 million in an initial public offering.
The company's lead candidates, WTX-124 and WTX-330, are molecules designed to selectively activate an immune response in the tumor microenvironment. The company plans to file INDs with the FDA for both programs in the 1H22, after which it plans to conduct Phase 1/1b trials in patients with multiple tumor types both as standalone treatments and in combination with an immune checkpoint inhibitor.
The Cambridge, MA-based company was founded in 2017 and plans to list on the Nasdaq under the symbol HOWL. Jefferies, SVB Leerink and Evercore ISI are the joint bookrunners on the deal. No pricing terms were disclosed.
